The influence of silybin on the hepatotoxic and hypoglycemic effects of praseodymium and other lanthanides.
In rats, i.v. administration of praseodymium, cerium and lanthanum (3 to 14 mg/kg) produced a dose-dependent increase in the serum activities of GOT, GPT and SDH. These dose-response curves of serum enzyme activities were shifted to the right by simultaneous treatment with silybin (75 mg/kg i.p.). Silybin also attenuated the increase of bromosulphthaleine retention and prevented the accumulation of liver triglycerides induced by praseodymium (7 mg/kg i.v.). Furthermore, silybin reduced the mortality rate of rats treated with high doses of the lanthanides. Rats treated with praseodymium (7 mg/kg i.v.) developed a pronounced hypoglycemia. On the 3rd day after praseodymium injection liver glycogen decreased to 4%, liver glutathione (GSH) to 82%, hepatic microsomal cytochrome P-450 content to 53%, aniline hydroxylase activity to 58% and aminophenazone demethylase activity to 40% of the control values. Silybin prevented praseodymium-induced hypoglycemia completely and the changes in the biochemical parameters of liver function partially but did not influence the decrease of liver GSH.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D004798:Enzymes / Q000097:blood; D005419:Flavonoids / Q000494:pharmacology*; D007003:Hypoglycemia / Q000517:prevention & control*; D008099:Liver / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D008674:Metals, Rare Earth / Q000037:antagonists & inhibitors* / Q000633:toxicity; D006899:Mixed Function Oxygenases / Q000378:metabolism; D011221:Praseodymium / Q000037:antagonists & inhibitors* / Q000633:toxicity; D051381:Rats; D012838:Silymarin / Q000494:pharmacology*
D001786:Blood Glucose; D004798:Enzymes; D005419:Flavonoids; D008112:Liver Glycogen; D008674:Metals, Rare Earth; D012838:Silymarin; D006899:Mixed Function Oxygenases; D011221:Praseodymium